Comparison · NCT02434523-ce2236ce
Amitriptyline vs Placebo: Lost to Follow up
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Amitriptyline vs Placebo: Lost to Follow up. Trial comparisons, record NCT02434523-ce2236ce. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02434523-ce2236ce
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.333 | 0.152 | 0.583 | wilson | |
| Risk in group 2 | 0.4 | 0.198 | 0.643 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0667 | -0.37 | 0.254 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.833 | 0.323 | 2.15 | log | |
| Odds ratio, group 1 over group 2 | 0.75 | 0.169 | 3.33 | log | |
| Number needed to treat, for one fewer participant with the outcome on Amitriptyline than on Placebo | 15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Amitriptyline | Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks | 5 | 15 | OG000 |
| Group 2 | Placebo | Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks | 6 | 15 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Lost to Follow up
- Description
- Time frame
- 8 weeks
- Population
- number of subjects in each arm who were lost to follow up
Source ClinicalTrials.gov
Trial
- Title
- Trial of the Treatment of Chronic Laryngitis With Amitryptiline
- NCT number
- NCT02434523
- Phases
- PHASE2, PHASE3
- Conditions
- Laryngeal Diseases, Chronic Laryngeal Neuropathy
- Interventions
- Amitriptyline, Placebo
- Lead sponsor
- Boston Medical Center
- Results first posted
- 2016-11-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02434523?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02434523-ce2236ce